Emerging Stocks Down Under 24 May 2022: Microba Life Sciences (ASX:MIO)

Microba Life Sciences: It’s been gut punched, but can it get back up again?

In recent weeks we’ve taken a look at some of the IPOs that have defied the market and went up in recent months – IPD Group (ASX: IPG), Atturra (ASX: ATA) and Ventia (ASX: VNT) being a few examples. Today we’re dissecting a debutante that has followed the market and we’re asking if it can recover – Microba Life Sciences (ASX: MAP). Microba is a biotech that is seeking to commercialise a technology that helps identify gut health problems.

Click here to read the previous edition of Emerging Stocks Down Under published 17 May 2022

For in-depth research reports or to keep up-to-date on the latest Stocks Down Under news see our parent company, Pitt Street Research, or follow us on Facebook and Twitter.